Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer
10.16352/j.issn.1001-6325.2024.02.0247
- VernacularTitle:华蟾素胶囊联合多西紫杉醇+顺铂化疗用于非小细胞肺癌患者的疗效
- Author:
Juan LI
1
;
Xiaofeng LI
;
Shengzhi XU
;
Kai TANG
Author Information
1. 浙江省荣军医院 消化肿瘤内科,浙江 嘉兴 341001
- Keywords:
cinobufotalin;
DP chemotherapy;
non-small cell lung cancer;
vascular endothelial growth factor;
disease control rate
- From:
Basic & Clinical Medicine
2024;44(2):247-251
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impacts of cinobufotalin combined with docetaxel+cisplatin chemotherapy on the disease control and the level of vascular endothelial growth factor(VEGF)in serum of patients with non-small cell lung cancer.Methods Totally 70 patients with non-small cell lung cancer admitted to Zhejiang Veteran Hospital from March 2019 to March 2022 were included.They were randomly divided into combination group(cinobufotalin combined with docetaxel+cisplatin,n= 35)and control group(docetaxel+cisplatin chemotherapy alone,n=35).The disease control rates of two groups,serum VEGF level,carcinoembryonic antigen(CEA),cy-tokeratin 19(CK19)and carbohydrate antigen 125(CA125)were measured using ELISA;life quality of patients was evaluated with the KPS score;The adverse events between two groups were compared.Results The disease control rate in the combination group(33/35,94.29%)was higher than that that of control group(25/35,71.43%,)(P<0.05).After treatment,the level of VEGF in both groups of patients decreased,and the KPS score increased(P<0.05)especially in the combination group(P<0.05).After treatment,the level of serum CEA,CA125,and CK19 of control group and combination group were obviously lower than those before treatment(P<0.05),while those in the combination group were even lower(P<0.05).The incidence of adverse events in the combination group(5/35,14.29%)was lower than that in the control group(13/35,37.14%)(P<0.05).Conclusions Cinobufotalin combined with docetaxel+cisplatin chemotherapy as a potential new chemotherapy significantly reduces the level of VEGF and tumor biomarkers in serum factor,improves the life quality of patients.The combined therapy is proved tobe safe.